🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Recruitingn/aAges 18 Years - anyAllPeking University Cancer Hospital & Institute
NCT06926179 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multicenter retrospective real-world study aims to evaluate the safety, efficacy and survival outcomes of neoadjuvant/induction immunotherapy in patients with non-small cell lung cancer (NSCLC). The study covers diverse treatment pathways, including surgery, definitive radiotherapy, and non-surgical strategies. It addresses gaps in existing trials by establishing a comprehensive cohort spanning neoadjuvant/induction therapy, perioperative management, and follow-up, providing real-world evidence to support treatment decisions in both operable and inoperable cases.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Histologically confirmed non-small cell lung cancer (NSCLC), regardless of the presence of EGFR or ALK sensitive driver gene mutations; 2. Clinical staging of IA-IIIC according to the AJCC 8th Edition before neoadjuvant treatment; 3. Received at least one cycle of neoadjuvant immunotherapy (with or without chemotherapy); 4. Assessed as resectable or potentially resectable by surgical experts prior to treatment. Exclusion Criteria: 1. Confirmed M1 disease; 2. History of previous lung malignancy or other metastatic malignant tumors; 3. Participation in other randomized controlled trials involving neoadjuvant treatment; 4. Significant missing clinical data.
💊

What it tests

  • neoadjuvant immunotherapy
📍

Where

4 sites
Peking University Cancer Hospital & Institute
Beijing, China
Peking University Third Hospital
Beijing, China
Inner Mongolia Hospital of Peking University Cancer Hospital
Hohhot, China
The Third Affliated Hospital of Kunming Medical University
Kunming, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy